{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T23:02:47Z","timestamp":1787612567469,"version":"build-2736575974"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,3,18]],"date-time":"2024-03-18T00:00:00Z","timestamp":1710720000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,3,18]],"date-time":"2024-03-18T00:00:00Z","timestamp":1710720000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100005565","name":"Janssen Global Services, LLC","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100005565","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1007\/s12325-024-02807-y","type":"journal-article","created":{"date-parts":[[2024,3,18]],"date-time":"2024-03-18T03:01:45Z","timestamp":1710730905000},"page":"1923-1937","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Adjusted Indirect Treatment Comparison of Progression-Free Survival with D-Rd and VRd Based on MAIA and SWOG S0777 Individual Patient-Level Data"],"prefix":"10.1007","volume":"41","author":[{"given":"Brian G. M.","family":"Durie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaji K.","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric M.","family":"Ammann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex Z.","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuchita","family":"Kaila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saad Z.","family":"Usmani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Facon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,18]]},"reference":[{"issue":"2","key":"2807_CR1","volume":"5","author":"MA Dimopoulos","year":"2021","unstructured":"Dimopoulos MA, Moreau P, Terpos E, et al. Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Hemasphere. 2021;5(2):e528.","journal-title":"Hemasphere"},{"key":"2807_CR2","unstructured":"Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Multiple Myeloma V2.2024. \u00a9 National Comprehensive Cancer Network, Inc. 2023. All rights reserved. Accessed Mar 5, 2024. To view the most recent and complete version of the guidelines, go online to NCCN.org. NCCN makes no warranties or any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way."},{"key":"2807_CR3","unstructured":"Kumar SK, Moreau P, Bahlis N, et al. Daratumumab plus lenalidomide and dexamethasone (D-Rd) versus lenalidomide and dexamethasone (Rd) alone in transplant ineligible patients with newly diagnosed multiple myeloma (NDMM): updated analysis of the phase\u00a03 MAIA study. Presented at: 64th American Society of Hematology (ASH) Annual Meeting & Exposition; December 10\u201313, 2022; New Orleans, LA."},{"issue":"10068","key":"2807_CR4","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/S0140-6736(16)31594-X","volume":"389","author":"BG Durie","year":"2017","unstructured":"Durie BG, Hoering A, Abidi MH, et al. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase\u00a03 trial. Lancet. 2017;389(10068):519\u201327.","journal-title":"Lancet"},{"issue":"11","key":"2807_CR5","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1016\/S1470-2045(21)00466-6","volume":"22","author":"T Facon","year":"2021","unstructured":"Facon T, Kumar SK, Plesner T, et al. Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase\u00a03 trial. Lancet Oncol. 2021;22(11):1582\u201396.","journal-title":"Lancet Oncol"},{"issue":"5","key":"2807_CR6","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/s41408-020-0311-8","volume":"10","author":"BGM Durie","year":"2020","unstructured":"Durie BGM, Hoering A, Sexton R, et al. Longer term follow-up of the randomized phase\u00a0III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT). Blood Cancer J. 2020;10(5):53.","journal-title":"Blood Cancer J"},{"issue":"1","key":"2807_CR7","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.jgo.2019.05.014","volume":"11","author":"H Mian","year":"2020","unstructured":"Mian H, Mian OS, Rochwerg B, Foley R, Wildes TM. Autologous stem cell transplant in older patients (age \u226565) with newly diagnosed multiple myeloma: a systematic review and meta-analysis. J Geriatr Oncol. 2020;11(1):93\u20139.","journal-title":"J Geriatr Oncol"},{"issue":"9","key":"2807_CR8","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","volume":"20","author":"BGM Durie","year":"2006","unstructured":"Durie BGM, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20(9):1467\u201373.","journal-title":"Leukemia"},{"issue":"18","key":"2807_CR9","doi-asserted-by":"publisher","first-page":"4691","DOI":"10.1182\/blood-2010-10-299487","volume":"117","author":"SV Rajkumar","year":"2011","unstructured":"Rajkumar SV, Harousseau JL, Durie B, et al. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood. 2011;117(18):4691\u20135.","journal-title":"Blood"},{"key":"2807_CR10","unstructured":"Phillippo DM, Ades AE, Dias S, Palmer S, Abrams KR, Welton NJ. NICE DSU Technical Support Document 18: Methods for population-adjusted indirect comparisons in submissions to NICE. http:\/\/www.nicedsu.org.uk. Accessed Jun 5, 2023."},{"issue":"15","key":"2807_CR11","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/j.jval.2012.05.004","volume":"2012","author":"J Signorovitch","year":"2012","unstructured":"Signorovitch J, Sikirica V, Erder MH, et al. Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research. Value Health. 2012;2012(15):940\u20137.","journal-title":"Value Health"},{"issue":"8","key":"2807_CR12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0160712","volume":"11","author":"S Reken","year":"2016","unstructured":"Reken S, Sturtz S, Kiefer C, Bohler YB, Wieseler B. Assumptions of mixed treatment comparisons in health technology assessments\u2014challenges and possible steps for practical application. PLoS ONE. 2016;11(8):e0160712.","journal-title":"PLoS ONE"},{"issue":"5","key":"2807_CR13","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1161\/CIRCOUTCOMES.113.000359","volume":"6","author":"MA Brookhart","year":"2013","unstructured":"Brookhart MA, Wyss R, Layton JB, Sturmer T. Propensity score methods for confounding control in nonexperimental research. Circ Cardiovasc Qual Outcomes. 2013;6(5):604\u201311.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"18","key":"2807_CR14","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1212\/WNL.0000000000012777","volume":"97","author":"PC Austin","year":"2021","unstructured":"Austin PC, Xin Yu AY, Vyas MV, Kapral MK. Applying propensity score methods in clinical research in neurology. Neurology. 2021;97(18):856\u201363.","journal-title":"Neurology"},{"issue":"3","key":"2807_CR15","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/00273171.2011.568786","volume":"46","author":"PC Austin","year":"2011","unstructured":"Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res. 2011;46(3):399\u2013424.","journal-title":"Multivariate Behav Res"},{"issue":"1","key":"2807_CR16","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1002\/mpr.329","volume":"20","author":"MJ Azur","year":"2011","unstructured":"Azur MJ, Stuart EA, Frangakis C, Leaf PJ. Multiple imputation by chained equations: what is it and how does it work? Int J Methods Psychiatr Res. 2011;20(1):40\u20139.","journal-title":"Int J Methods Psychiatr Res"},{"issue":"1","key":"2807_CR17","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1198\/000313007X172556","volume":"61","author":"NJ Horton","year":"2007","unstructured":"Horton NJ, Kleinman KP. Much ado about nothing: a comparison of missing data methods and software to fit incomplete data regression models. Am Stat. 2007;61(1):79\u201390.","journal-title":"Am Stat"},{"issue":"434","key":"2807_CR18","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1080\/01621459.1996.10476908","volume":"91","author":"DB Rubin","year":"1996","unstructured":"Rubin DB. Multiple imputation after 18+ years. J Am Stat Assoc. 1996;91(434):473\u201389.","journal-title":"J Am Stat Assoc"},{"key":"2807_CR19","unstructured":"SWOG Cancer Research Network, National Cancer Institute (NCI). Comparing combinations of drugs to treat newly diagnosed multiple myeloma (NDMM) when a stem cell transplant is not a medically suitable treatment. ClinicalTrials.gov Identifier: NCT05561387. Updated Oct 25, 2023. https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05561387. Accessed Jan 2, 2024."},{"issue":"suppl 1","key":"2807_CR20","doi-asserted-by":"publisher","first-page":"10009","DOI":"10.1182\/blood-2022-165591","volume":"140","author":"BGM Durie","year":"2022","unstructured":"Durie BGM, Lam A, Ngo M, Pei H, Ammann EM. Post-hoc analysis of efficacy and safety in the SWOG S0777 trial stratified by age. Blood. 2022;140(suppl 1):10009\u201310.","journal-title":"Blood"},{"issue":"12","key":"2807_CR21","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1002\/ajh.25963","volume":"95","author":"BGM Durie","year":"2020","unstructured":"Durie BGM, Kumar SK, Usmani SZ, et al. Daratumumab-lenalidomide-dexamethasone vs standard-of-care regimens: efficacy in transplant-ineligible untreated myeloma. Am J Hematol. 2020;95(12):1486\u201394.","journal-title":"Am J Hematol"},{"issue":"5","key":"2807_CR22","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1016\/j.jval.2014.06.001","volume":"17","author":"A Laws","year":"2014","unstructured":"Laws A, Kendall R, Hawkins N. A comparison of national guidelines for network meta-analysis. Value Health. 2014;17(5):642\u201354.","journal-title":"Value Health"},{"issue":"5","key":"2807_CR23","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.1007\/s12325-022-02083-8","volume":"39","author":"T Facon","year":"2022","unstructured":"Facon T, San-Miguel J, Dimopoulos MA, et al. Treatment regimens for transplant-ineligible patients with newly diagnosed multiple myeloma: a systematic literature review and network meta-analysis. Adv Ther. 2022;39(5):1976\u201392.","journal-title":"Adv Ther"},{"issue":"11","key":"2807_CR24","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/s41408-018-0141-0","volume":"8","author":"PG Richardson","year":"2018","unstructured":"Richardson PG, San Miguel JF, Moreau P, et al. Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting. Blood Cancer J. 2018;8(11):109.","journal-title":"Blood Cancer J"},{"issue":"1","key":"2807_CR25","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1186\/s12885-022-09980-9","volume":"22","author":"R Medhekar","year":"2022","unstructured":"Medhekar R, Ran T, Fu AZ, Patel S, Kaila S. Real-world patient characteristics and treatment outcomes among nontransplanted multiple myeloma patients who received bortezomib in combination with lenalidomide and dexamethasone as first line of therapy in the United States. BMC Cancer. 2022;22(1):901.","journal-title":"BMC Cancer"},{"issue":"1","key":"2807_CR26","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.clml.2023.09.003","volume":"24","author":"L Gordan","year":"2024","unstructured":"Gordan L, Tan CR, Vescio R, et al. Progression-free survival of daratumumab vs. bortezomib triplet combination with lenalidomide and dexamethasone in transplant ineligible patients with newly diagnosed multiple myeloma: TAURUS chart review study. Clin Lymphoma Myeloma Leuk. 2024;24(1):55\u201363.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"36","key":"2807_CR27","doi-asserted-by":"publisher","first-page":"3983","DOI":"10.2217\/fon-2022-0933","volume":"18","author":"T Ran","year":"2022","unstructured":"Ran T, Medhekar R, Fu AZ, Patel S, Kaila S. Patient characteristics associated with dose modifications for VRd among newly diagnosed multiple myeloma patients. Future Oncol. 2022;18(36):3983\u201391.","journal-title":"Future Oncol"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-02807-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-024-02807-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-02807-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,26]],"date-time":"2024-04-26T17:12:22Z","timestamp":1714151542000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-024-02807-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,18]]},"references-count":27,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["2807"],"URL":"https:\/\/doi.org\/10.1007\/s12325-024-02807-y","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,18]]},"assertion":[{"value":"1 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Brian G.M. Durie is a consultant for Amgen, Celgene, Johnson & Johnson, and Takeda. Shaji K. Kumar received research funding from AbbVie, Allogene, Amgen, AstraZeneca, Bristol Myers Squibb, CARsgen, GSK, Janssen, Novartis, Roche-Genentech, Takeda, Regeneron, and Molecular Templates; served as a consultant or on an advisory board (with no personal payments) for AbbVie, Amgen, Bristol Myers Squibb, Janssen, Roche-Genentech, Takeda, AstraZeneca, bluebird bio, Epizyme, Secura Bio, Monte Rosa Therapeutics, Trillium, Loxo Oncology, K36, Sanofi, and Arcellx; and served as a consultant or on an advisory board (with personal payments) for Oncopeptides, BeiGene, Antengene, and GLH Pharma. Eric M. Ammann, Alex Z. Fu, Shuchita Kaila, and Annette Lam are employees of Janssen and hold equity in a publicly traded company. Saad Z. Usmani received research funding from Amgen, Array BioPharma, Bristol Myers Squibb, Celgene, GSK, Janssen, Merck, Pharmacyclics, Sanofi, Seattle Genetics, SkylineDx, and Takeda; served as a consultant for AbbVie, Amgen, Bristol Myers Squibb, Celgene, Edo Pharma, Genentech, Gilead, GSK, Janssen, Oncopeptides, Sanofi, Seattle Genetics, Secura Bio, SkylineDx, Takeda, and TeneoBio; and served as a speaker for Amgen, Bristol Myers Squibb, Janssen, and Sanofi. Thierry Facon served as a consultant or advisor for Janssen, Bristol Myers Squibb, Roche, and Takeda; and served on a speakers bureau for Janssen and Bristol Myers Squibb.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The MAIA and SWOG S0777 trials were conducted in accordance with the principles of the Declaration of Helsinki, with study protocols approved by independent ethics committees and\/or institutional review boards at each site. All patients provided written informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}